Error message

User warning: The following theme is missing from the file system: WORKING_COPY. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1156 of /home/insysbi8/insysbio.com/docs/includes/bootstrap.inc).

Posters & Presentations

2020

AAIC Virtual Event

  • Poster: Description of amyloid beta influence on synaptic plasticity and tau hyperphosphorylation by mechanistic quantitative systems pharmacology model
    Authors: Stepan Lerner, Tatiana Karelina

AACR Virtual Annual Meeting II

  • Poster: Prediction and comparison of PD-1 receptor occupancy in the tumor after treatment with immune checkpoint inhibitors
    Authors: Dmitry Shchelokov, Oleg Demin Jr
  • Poster: Prediction of target receptor occupancy for ALX148, a CD47 blocker, using mechanistic PK/RO modeling
    Authors:Elena Vasileva12, Oleg Demin Jr2
    Affiliation: 1 Lomonosov Moscow State University, Moscow, Russia; 2InSysBio, Moscow, Russia

121st ASCPT Annual meeting (cancelled in response to COVID-19 spread)

  • Poster: Quantitative systems pharmacology model of Alzheimer’s disease predicts effect of tau directed immunotherapy on multiple biomarkers
    Authors: Tatiana Karelina, Oleg Demin

2019

61st ASH Annual Meeting & Exposition, Orlando, FL, US

  • Poster: A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies
    Authors: Srikumar Sahasranaman1, Oleg Demin Jr2, Dmitry Shchelokov2, Veronika Musatova2, Nageshwar Budha1, Ying Ou2
    Affiliation: 1Clinical Pharmacology, BeiGene USA, Inc.; 2InSysBio, Moscow, Russia.

SITC 2019, National Harbor, MD, US

  • Poster: Prediction of target occupancy in tumor after treatment with anti-PD1 antibodies using physiologically based pharmacokinetic modeling
    Authors: Oleg Demin Jr, Dmitry Shchelokov
  • Poster: Quantitative systems pharmacology modeling of B-cell acute lymphoblastic leukemia treatment with bispecific T-cell engaging antibodies for investigation of bell-shaped dose response
    Authors: Oleg Demin Jr

ACoP10, Orlando, FL, US

  • Presentation: AD pathology QSP platform: studying the interactions between different toxicity modules through the junction of mechanistic submodels
    Speaker: Tatiana Karelina
  • Poster: Physiologically based pharmacokinetic and receptor occupancy (PBPK/RO) modeling of anti-PD1 monoclonal antibodies
    Authors: Oleg Demin Jr, Dmitry Shchelokov
  • Poster: Investigation of bell-shaped dose response of bispecific T-cell engaging antibodies under physiological conditions
    Author: Oleg Demin Jr
  • Poster: Quantitative systems pharmacology model of COPD progression with implemented standard of care treatments (LABA/ICS)
    Authors: Galina Lebedeva1, Mikhail Benkov1, Oleg Demin1, Loveleena Bansal2, Cibele Falkenberg2, Martin Hingle3, Valeriu Damian2
    Affiliation: 1InSysBio, Moscow, Russia; 2GSK, Collegeville, PA; 3GSK, Stevenage, UK
  • Poster: LikelihoodProfiler is a software package for practical identifiability analysis for the large-scale dynamic models
    Authors: Ivan Borisov, Evgeny Metelkin
  • Poster: Development of quantitative systems pharmacology  (QSP) model of systemic lupus erythematosus and its application to explore possible mechanisms of alterations in serum IFN1 resulting from anti-IFNAR1 treatment
    Authors: Sergey Smirnov1, Alexsandra Diakonova1, Oleg Demin1, Christopher Morehouse2, Dominic Sinibaldi2, Raj Tummala3, Denison Kuruvilla4, Yen Len Chia4, Lorin K. Roskos2, Wendy I. White2
    Affiliation: 1InSysBio, Moscow, Russia; 2MedImmune, Gaithersburg, MD USA; 3AstraZeneca Gaithersburg, MD USA; 4MedImmune, San Francisco, CA USA
  • Poster: Influence of neuronal protein degradation pathways on  tau pathology studied by Quantitative Systems Pharmacology model
    Authors: Mark Meerson1, Tatiana Karelina1 and Diana Сlausznitzer2
    Affiliation: 1InSysBio, Moscow, Russia; 2AbbVie, Ludwigshaven, Germany
  • Poster: From stem cell to erythrocyte and platelet: QSP model of erythropoiesis and thrombopoiesis for assessing the impact of pharmacological interventions
    Authors: Alexander Stepanov, Galina Lebedeva
  • Poster: Workflow for development of QSP models of Immune Response requires appropriate software infrastructure
    Authors: Tatiana Karelina
    • , Sergey Smirnov, Galina Lebedeva, Oleg Demin Jr, Evgeny Metelkin, Nail Gizzatkulov
  • Poster: ’Heta’ is a new declarative language to define the large-scale systems pharmacology and systems biology models
    Author: Evgeny Metelkin
  • Poster: PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release
    Authors: Evgeny Metelkin, Oleg Demin
  • Poster: In vitro to in vivo extrapolation of CD4 T cell polarization in lymph nodes using QSP modeling
    Authors: Oleg Demin, Svetlana Rubina, Dmitry Shchelokov, Oleg Demin Jr
  • Poster: QSP model of human granulopoiesis and neutrophil homeostasis for assessment of pharmacological interventions
    Authors: Galina Lebedeva, Alexander Stepanov

PAGE 2019, Stockholm, Sweden

  • Poster: Quantitative Systems Pharmacology model of key intraneuronal pathways regulating toxic protein accumulation
    Authors: Mark Meerson1, Tatiana Karelina1 and Diana Сlausznitzer2
    Affiliation: 1InSysBio, Moscow, Russia, 2AbbVie, Ludwigshaven, Germany
  • Poster: Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies
    Authors: Dmitry Shchelokov, Oleg Demin Jr
  • Poster: Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects
    Author: Tatiana Karelina
  • Poster: Application of different approaches to generate virtual patient populations for QSP model of physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies
    Authors: Galina Kolesova, Oleg Demin, Evgeny Metelkin and Dmitry Shchelokov

PEGS 2019, Boston, MA, US

  • Poster: Selection of First-in-Human Study Dose for Antibodies and Antibody Constructs Using Quantitative Systems Pharmacology Modeling
    Authors: Oleg Demin Jr, Dmitry Shchelokov

AACR Annual Meeting 2019, Atlanta, GA, US

  • Poster: Quantitative systems pharmacology modeling of immunotherapies in B-cell acute lymphoblastic leukemia
    Authors: Oleg Demin Jr, Antonina Nikitich, Oleg Demin
  • Poster: Implementation of inter-patient variability in semi-mechanistic model of melanoma treatment with vemurafenib
    Authors: Dmitry Shchelokov, Oleg Demin Jr, Oleg Demin

2018

BiotechClub, Moscow, Russia

  • Presentation: Application of mathematical modeling in drug research and development
    Speaker: Oleg Demin
  • Presentation: Application of QSP modeling in immuno-oncology
    Speaker: Oleg Demin Jr

ICSB 2018, Lyon, France

  • Poster: SBML viewer is a tool for transformation of systems biology models to human-readable format
    Authors: Viktoria Tkachenko , Evgeny Metelkin
  • Poster: An algorithm for practical identifiability analysis and confidence intervals evaluation based on constrained optimization
    Authors: Ivan Borisov, Evgeny Metelkin

ACoP9, San Diego, CA, US

  • Presentation: Quantitative systems pharmacology model for amyloid pathology investigation
    Speaker: Tatiana Karelina
  • Poster: Quantitative Systems Pharmacology (QSP) model of bispecific T-Cell engaging antibody constructs for Acute Myeloid Leukemia treatment
    Authors: Oleg Demin Jr1, Svetlana Rubina1, Theresa Yuraszeck2, Khamir Mehta2, Vaishali Chudasama2, Matthias Klinger3, Cedric Dos Santos2, Oleg Demin1, Sergey Ermakov2
    Affiliation: 1InSysBio, Moscow, Russia; 2Amgen Inc., Thousand Oaks, CA, USA; 3Amgen Research (Munich), Germany
  • Poster: Translational quantitative systems pharmacology model of tau pathology in human and mouse for immunotherapy investigation
    Authors: Tatiana Karelina, Alexander Stepanov
  • Poster: Identification of parameters of QSP models responsible for observed variability in experimental data
    Authors: Galina Kolesova, Oleg Demin

AAIC 2018, Chicago, IL, USA

  • Poster: Translational quantitative systems pharmacology model of tauopathies
    Authors: Tatiana Karelina, Alexander Stepanov
  • Poster: Description of different amyloid toxic species and pathology progression by mechanistic quantitative systems pharmacology model
    Authors: Tatiana Karelina, Alexander Stepanov, Alena Zhukova

PAGE 2018, Montreux, Switzerland

  • Poster: A semi-mechanistic model of targeted therapy for melanoma
    Authors: Dmitrii Shchelokov, Oleg Demin Jr
  • Poster: Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
    Authors: Tatiana Karelina, Alexander Stepanov, Oleg Demin
  • Poster: Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment
    Authors: Etienne Pigeolet1, Konstantinos Biliouris2, Ulf Neumann3, Alexandra Urusova4, Oleg Demin4, Tatiana Karelina4
    Affiliation: 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Institute for Biomedical Research, Cambridge, USA; 3Novartis Institute for Biomedical Research, Basel, Switzerland; 4InSysBio, Moscow, Russia

AAT-AD/PD Focus Meeting, Torino, Italy

  • Presentation: In silico implementation of tauopathy transgenic mouse model
    Speaker: Alexander Stepanov

ASCPT 2018, Orlando, FL, USA

  • Poster: PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release
    Authors: Evgeny Metelkin, Oleg Demin
  • Poster: Translational QSP model of amyloid beta allows to predict both short and long term response of AD patients to different therapies
    Authors: Tatiana Karelina1, Oleg Demin1, Oleg Demin Jr1, Timothy Nicholas2
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
  • Poster: Multiple myeloma quantitative systems pharmacology model: development and usage for pomalidomide influence evaluation
    Authors: Svetlana Rubina, Oleg Demin, Oleg Demin Jr

2017

ACoP8, Fort Lauderdale, FL, US

  • Poster: Mechanistic model for the role of the microgliall cells in amyloid accumulation and its modulation by immunotherapy
    Authors: Tatiana Karelina1, Alexander Stepanov1, Theresa Yuraszeck2, Dean Hickman2, Steve Wood2
    Affiliation: 1InSysBio, Moscow, Russia; 2Amgen Inc., Thousand Oaks, CA, USA
  • Poster: Tau propagation system pharmacology model based on three-component memory-retrieval system predicts heterogeneous response to immunotherapy in brain regions
    Authors: Tatiana Karelina1, Alexander Stepanov1, Timothy Nicholas2
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
  • Poster: A Quantitative Systems Pharmacology Model of Asthma
    Authors: Sergey Smirnov1, Galina Lebedeva1, Oleg Demin1, Tatiana Petukhova1, Lourdes Cucurull-Sanchez2, David Fairman2
    Affiliation: 1InSysBio, Moscow, Russia; 2GSK Medicines Research Centre, Stevenage, UK
  • Poster: Model-based analysis of clinical assays for assessing the efficacy of vaccines against Respiratory Syncytial Virus (RSV)
    Authors: Galina Lebedeva, Nikolai Pakhomov, Oleg Demin, Oleg Demin Jr
  • Poster: Evaluation  of Potential Low-Dose Regimens of Oral Fixed-Dose Combination of Cytidine Deaminase Inhibitor E7727 with Decitabine (ASTX727-LD) to Minimize Decitabine-Mediated Neutropenia in Low-Risk MDS Subjects Using Systems Pharmacology Modeling
    Authors: Antonina Nikitich1, Oleg Demin1, Oleg Demin Jr1, Aram Oganesian2
    Affiliation: 1InSysBio, Moscow, Russia; 2Astex Pharmaceuticals Inc., Pleasanton, CA

7th German-Russian Week of the Young Researcher, Moscow, Russia

  • Poster: SbmlViewer is a visualization tool for systems biology modeling
    Authors: Viktoria Tkachenko, Evgeny Metelkin

AD/PD 2017, Vienna, Austria

  • Poster: Amyloid toxicity and different mechanisms of action for amyloid-targeted treatments studied by quantitative systems pharmacology model
    Authors: Tatiana Karelina1, Timothy Nicholas2
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA

ASCPT 2017, Washington DC, US

  • Poster: Mechanistic model of neutrophil cell dynamics and activation to inform systems pharmacology modeling of the immune response
    Authors: Galina Lebedeva, Sergey Smirnov, Evgeny Metelkin, Oleg Demin
  • Poster: Mathematical description of multiple effects of regulatory molecules
    Authors: Sergey Smirnov, Evgeny Metelkin, Galina Lebedeva, Oleg Demin

2016

ACoP7, Bellevue, WA, US

  • Presentation: Mechanistic approach to describe multiple effects of regulatory molecules on cell dynamics process in immune response
    Authors: Oleg Demin, Evgeny Metelkin, Galina Lebedeva, Sergey Smirnov
  • Poster: Quantitative systems pharmacology model of amyloid pathology allows for clinical endpoint prediction and hypothesis testing
    Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
  • Poster: Exploration of differences between mechanism-based PK/PD and systems pharmacology models
    Authors: Oleg Demin
  • Poster: Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach
    Authors: Oleg Demin Jr

PAGE 2016, Lisboa, Portugal

  • Poster: Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics
    Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
    Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US

The International Liver Congress 2016, Barcelona, Spain

  • Poster: Quantitative Systems Pharmacology model of Hepatitis C: Prediction of Results of Ongoing Clinical Trials of Direct Antiviral Agents Combination Therapies
    Authors: Oleg Demin Jr

ASCPT 2016, San Diego, CA, US

  • Poster: Analysis of brain pharmacodynamics of gamma-secretase inhibitors using quantitative translational systems pharmacology model
    Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
  • Poster: Population modeling study for evaluation of effective and safe dose of RPH-104 for the treatment of Behcet’s syndrome and FMF
    Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
    Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US
  • Poster: Systems Pharmacology Model Of Hepatitis C: Exploration Of Effect Of Combinations Of Direct Antiviral Agents On HCV Production During Treatment Of HCV Patients
    Authors: Oleg Demin Jr, Oleg Demin
  • Poster: Population modeling and simulation of RPH-203 effects in the context of prevention of skeletal-related events in patients with bone metastases
    Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Shorena Archuadze2, Galina Konopleva2, Dmitry Koloda2, Mikhail Samsonov2
    Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia

2015

ASCPT 2015, New Orleans, LA, US

  • Poster: Systems Pharmacology Modeling of Hypomethylating agents Decitabine and SGI-110 for Evaluation of AML treatment by targeting the S-phase with prolonged Pharmacokinetic exposures
    Authors: Aram Oganesian1, Oleg Demin Jr2, Antonina Nikitich2, Oleg Demin2 and Mohammad Azab1
    Affiliation: 1Astex Pharmaceuticals Inc., Dublin, CA, US; 2InSysBio, Moscow, Russia

20th Congress of EHA, Vienna, Austria

  • Poster: Application of Systems Pharmacology Modeling for Evaluation of Therapies Effect on Blast Dynamics in Acute Lymphoblastic Leukemia
    Authors: Antonina Nikitich, Oleg Demin Jr

2014

Systems Pharmacology in Drug Discovery & Development, Noordwijkerhout, The Netherlands

  • Poster: A systems pharmacology model of purine metabolism to explore novel options for the treatment of Gout
    Authors: Pinky Dua1, Oleg Demin Jr2, Viktor Sokolov2, Tatiana Yakovleva2, Oleg Demin2, Piet van der Graaf1, 3
    Affiliation: 1Clinical Pharmacology, Pfizer Neusentis, Cambridge UK; 2InSysBio, Moscow, Russia; 3Leiden Academic Centre for Drug Research (LACDR), The Netherland

ASCPT 2014, Atlanta, GE, US

  • Poster: Systems Pharmacology Modeling of Calcium and Phosphate Metabolism in Chronic Kidney Disease
    Authors: Antonina Bakhmutova, Oleg Demin Jr, Oleg Demin
  • Poster: Development and Application of Systems Pharmacology Model to Predict Nausea Resulted from Administration GLP-1 Agonists
    Authors: Veronika Voronova, Oleg Demin Jr, Sergei Smirnov, Oleg Demin

EMBL-EBI Industry Systems Pharmacology Workshop, Cambridge, UK

  • Presentation: Systems pharmacology modeling in drug research and development: application of modeling technique
    Speaker: Oleg Demin

2013

ACoP4, Fort Lauderdale, FL, US

  • Poster: Development of a Human System Pharmacology Model to Characterize Diabetic Nephropathy Disease Progression and the Effect of Standard of Care Therapy
    Authors: Danny Chen1, Veronika Voronova2, Sergey Smirnov2, Evgeny Metelkin2, Ekaterina Goryacheva2, Antonina Bahmutova2, Oleg Demin2
    Affiliation: 1Pfizer Inc. Cambridge, MA; 2InSysBio, Moscow, Russia

ASCPT 2013, Indianapolis, IN, US

  • Presentation: Systems Pharmacology Modeling in Research and Development
    Speaker: Oleg Demin
  • Poster: Exploration of molecular mechanisms underlying susceptibility of HCV patients to IFN-? therapy via systems pharmacology modeling
    Authors: Oleg Demin1, Sergey Smirnov1, Neil Benson2, Piet H. van der Graaf2, Victoria Flores2, Ekaterina Goryacheva1, Oleg Demin1
    Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer, Sandwich, UK

Archive